Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field
{{output}}
Background: During the COVID-19 pandemic, Mesenchymal Stromal Cells (MSCs) were rapidly proposed as a therapeutic option for Acute Respiratory Distress Syndrome (ARDS) based on their immunomodulatory properties. We report the res... ...
